» Articles » PMID: 29701875

Estimation of the Optimal Surrogate Based on a Randomized Trial

Overview
Journal Biometrics
Specialty Public Health
Date 2018 Apr 28
PMID 29701875
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

A common scientific problem is to determine a surrogate outcome for a long-term outcome so that future randomized studies can restrict themselves to only collecting the surrogate outcome. We consider the setting that we observe n independent and identically distributed observations of a random variable consisting of baseline covariates, a treatment, a vector of candidate surrogate outcomes at an intermediate time point, and the final outcome of interest at a final time point. We assume the treatment is randomized, conditional on the baseline covariates. The goal is to use these data to learn a most-promising surrogate for use in future trials for inference about a mean contrast treatment effect on the final outcome. We define an optimal surrogate for the current study as the function of the data generating distribution collected by the intermediate time point that satisfies the Prentice definition of a valid surrogate endpoint and that optimally predicts the final outcome: this optimal surrogate is an unknown parameter. We show that this optimal surrogate is a conditional mean and present super-learner and targeted super-learner based estimators, whose predicted outcomes are used as the surrogate in applications. We demonstrate a number of desirable properties of this optimal surrogate and its estimators, and study the methodology in simulations and an application to dengue vaccine efficacy trials.

Citing Articles

A Narrative Review of High Throughput Wastewater Sample Processing for Infectious Disease Surveillance: Challenges, Progress, and Future Opportunities.

Shanmugam B, Alqaydi M, Abdisalam D, Shukla M, Santos H, Samour R Int J Environ Res Public Health. 2024; 21(11).

PMID: 39595699 PMC: 11593539. DOI: 10.3390/ijerph21111432.


Group sequential testing of a treatment effect using a surrogate marker.

Parast L, Bartroff J Biometrics. 2024; 80(4).

PMID: 39377516 PMC: 11459368. DOI: 10.1093/biomtc/ujae108.


Flexible evaluation of surrogate markers with Bayesian model averaging.

Duan Y, Parast L Stat Med. 2023; 43(4):774-792.

PMID: 38081586 PMC: 10897582. DOI: 10.1002/sim.9986.


A controlled effects approach to assessing immune correlates of protection.

B Gilbert P, Fong Y, Kenny A, Carone M Biostatistics. 2023; 24(4):850-865.

PMID: 37850938 PMC: 10583729. DOI: 10.1093/biostatistics/kxac024.


Patient-important outcomes in clinical trials of atopic diseases and asthma in the last decade: A systematic review.

Gonzalez-Diaz S, Garcia-Campa M, Noyola-Perez A, Guzman-Avilan R, De Lira-Quezada C, Alvarez-Villalobos N World Allergy Organ J. 2023; 16(4):100769.

PMID: 37179537 PMC: 10172603. DOI: 10.1016/j.waojou.2023.100769.


References
1.
Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384(9951):1358-65. DOI: 10.1016/S0140-6736(14)61060-6. View

2.
Joffe M . Discussion on "surrogate measures and consistent surrogates". Biometrics. 2013; 69(3):572-5. DOI: 10.1111/biom.12074. View

3.
Prentice R . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4):431-40. DOI: 10.1002/sim.4780080407. View

4.
Villar L, Dayan G, Arredondo-Garcia J, Rivera D, Cunha R, Deseda C . Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2014; 372(2):113-23. DOI: 10.1056/NEJMoa1411037. View

5.
Daniels M, Hughes M . Meta-analysis for the evaluation of potential surrogate markers. Stat Med. 1997; 16(17):1965-82. DOI: 10.1002/(sici)1097-0258(19970915)16:17<1965::aid-sim630>3.0.co;2-m. View